MarketCap
Facebook
X
Telegram
Apellis Pharmaceuticals Operating Cash Flow | APLS
Annual Operating Cash Flow Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.3 M | -87.9 M | -595 M | -514 M | -563 M | -160 M | -211 M | -131 M | -46.6 M | -26 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.3 M | -595 M | -229 M |
Quarterly Operating Cash Flow Apellis Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61 M | 59.5 M | - | -53.4 M | - | - | - | -133 M | - | - | - | -178 M | - | -373 M | -219 M | -112 M | - | -451 M | -282 M | -153 M | - | -302 M | -203 M | -108 M | - | -129 M | -75.5 M | -35.6 M | - | -86.8 M | -53.6 M | -22.9 M | - | -31.1 M | -19.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 59.5 M | -451 M | -137 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
19 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-47.1 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-141 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
15.5 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-101 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
-93.6 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
-196 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-75 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-55.2 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
50.4 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-74.5 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
-368 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-78.2 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
-81.8 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
-4.37 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-45.4 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
-122 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
-38.3 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
-89.2 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
-76.7 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-77 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
-26.8 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
-153 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
-73.2 M | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
-100 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
-117 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
-77.1 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
-65.4 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
-386 M | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
-20.5 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
28.2 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-19 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
-31.1 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-1.52 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-45 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
-571 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
-31.4 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
-37.2 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-10.5 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-2.6 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
-70.3 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
-61.7 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-32.1 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-32.2 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
1.93 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-76 M | - | 1.02 % | $ 90.8 M | Britain |